What is the latest price of pemetinib/pemetinib in 2025?

Pemigatinib (Pemigatinib) is an oral targeted drug targeting the FGFR2 fusion or rearrangement gene. It is mainly suitable for patients with advanced or metastatic cholangiocarcinoma (CCA), especially those whose disease has progressed after standard chemotherapy. Its mechanism of action is to inhibit the FGFR signaling pathway, thereby blocking the proliferation and survival of tumor cells and providing precise treatment options for such patients. Before treatment, the FGFR2 fusion or rearrangement status must be confirmed through molecular testing to ensure the effectiveness and safety of the drug. With standardized management, most patients can complete treatment safely while maintaining a good quality of life.

In the domestic market, pemetinib is already on the market but has not yet been included in medical insurance. Common specifications include4.5mg 14 tablets and 9mg 14 tablets, with the price per box ranging from RMB 20,000 to RMB 50,000. The selling price in overseas markets is relatively higher. Taking 13.5mg 14 tablets as an example, the price per box may reach more than RMB 70,000, which may fluctuate due to exchange rates. For overseas consumers, some countries provide generic versions of pemetinib, whose ingredients are basically the same as the original drug. For example, 14 tablets of 4.5 mg produced by Lucius Pharmaceuticals in Laos are priced at more than 700 yuan per box, which provides a more feasible option for patients with higher financial burdens.

The price range of pemetinib is relatively large, mainly related to specifications, origin and whether it is an original drug or a generic drug. Because the drug targets a relatively limited patient population and has limited market supply, prices remain high. At the same time, patients must strictly follow the doctor's instructions when using it and plan the course of treatment reasonably to reduce the financial burden and risk of side effects. Overall, pemetinib is a precise targeted drug with clear indications. Although it is expensive, it has obvious clinical value. It is an important treatment option especially for patients with cholangiocarcinoma who are refractory to traditional chemotherapy.

Reference materials:https://go.drugbank.com/drugs/DB15102